Ctt Pharmaceutical Holdings Stock Investor Sentiment

CTTH Stock  USD 0.06  0  6.19%   
Under 62% of CTT Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading CTT Pharmaceutical Holdings pink sheet suggests that many investors are alarmed at this time. CTT Pharmaceutical's investing sentiment shows overall attitude of investors towards CTT Pharmaceutical Holdings.
  
over a month ago at news.google.com         
ASX Winners And Losers Of Today 18-10-24 - FN Arena News
Google News at Macroaxis
over two months ago at news.google.com         
CTT Pharmaceutical Holdings CEO acquires shares worth 41 - Investing.com
Google News at Macroaxis
over two months ago at news.google.com         
CTT Pharmaceutical Holdings CEO acquires shares worth 60 - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
CTT Pharmaceutical Holdings CEO acquires 145 in company stock - Investing.com India
Google News at Macroaxis
over three months ago at news.google.com         
Ctt pharmaceutical holdings CEO buys shares worth 52 - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
CTT Pharmaceutical CEO buys 42 in company stock - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
Ctt pharmaceutical CEO buys 64 worth of company stock - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
Ctt pharmaceutical CEO buys 68 worth of company stock - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
CTT Pharmaceutical CEO acquires shares worth 100 - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
CTT Pharmaceutical Holdings CEO buys 108 in company stock - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
CTT Pharmaceutical Holdings CEO buys 64 worth of company shares By Investing.com - Investing.com Nig...
Google News at Macroaxis
over three months ago at news.google.com         
Insight venture partners executives sell over 61 million in nCino shares By Investing.com - Investin...
Google News at Macroaxis
over three months ago at news.google.com         
Ctt pharmaceutical holdings CEO buys shares worth 163 - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
Spirax-Sarco shares rating upgraded to neutral by Exane BNP Paribas By Investing.com - Investing.com...
Google News at Macroaxis
over three months ago at news.google.com         
Gitlab CFO sells over 1.17 million in company stock By Investing.com - Investing.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about CTT Pharmaceutical that are available to investors today. That information is available publicly through CTT media outlets and privately through word of mouth or via CTT internal channels. However, regardless of the origin, that massive amount of CTT data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CTT Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CTT Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CTT Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CTT Pharmaceutical alpha.

CTT Pharmaceutical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for CTT Pink Sheet analysis

When running CTT Pharmaceutical's price analysis, check to measure CTT Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CTT Pharmaceutical is operating at the current time. Most of CTT Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of CTT Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CTT Pharmaceutical's price. Additionally, you may evaluate how the addition of CTT Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas